Commercialization of MSCs
MSCs were first commercialized by Dr. Caplan when he partnered with Peter Freidli, serial entrepreneur Kevin Kimberlin and Spencer Trask & Co. Together they launched Osiris Therapeutics, a company that initially focused on using MSCs for the treatment of a rare, devastating disease in children called Graft-versus-Host-Disease (GvHD). Osiris developed its proprietary drug Prochymal (i.e., remestemcel-L) and shepherded this MSC-based therapy through clinical trials and secured the world’s first approved systemically delivered cell therapy to allow the advancement and application of MSCs into the marketplace. Prochymal was sold to Australia-based Mesoblast and renamed Ryoncil in 2012, but Osiris continued to expand its work and product to cover many other applications of MSCs within the field of regenerative medicine. *The FDA is currently reviewing Ryoncil for use in the United States and should reach its decision by September 30, 2020.